Company touted Kisqali's "replacement power" as another blockbuster faces generic competition and expressed optimism about ...

The privately funded basket trial makes good on its aim to enroll underrepresented groups amid a DEI-hostile federal funding ...

A 51-year-old man with limb-girdle muscular dystrophy died after receiving Sarepta's experimental gene therapy and experiencing acute liver failure.

The firm will combine every 15 shares into one share in order to comply with Nasdaq's minimum bid price requirement.

In a final draft guidance, the committee recommended the treatment for HR-positive HER2-negative early breast cancer patients, regardless of lymph node involvement.

For $1.8 million upfront and additional contingent and milestone payments, I-Mab gains full rights to givastomig's parental antibody.

NEW YORK – Sarepta Therapeutics on Wednesday said it would pivot to focus its rare genetic disease pipeline on siRNA drugs as part of a strategic restructuring plan to prioritize "high-value, high ...

While NICE recommended the drug for patients with at least one F508del mutation, Vertex struck a reimbursement deal with NHS England for a broader population.

The participating regions are home to 84 percent of sickle cell Medicaid patients who could gain access to gene therapies under outcomes-based agreements.